GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India · Delayed Price · Currency is INR 2,201.15
+76.50 (3.60%)
At close: Jun 16, 2026
BOM:500660 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 38,217 | 37,492 | 34,537 | 32,517 | 32,780 | |
Revenue Growth (YoY) | 1.93% | 8.56% | 6.21% | -0.80% | 12.05% |
Cost of Revenue | 13,756 | 14,139 | 13,552 | 13,041 | 13,782 |
Gross Profit | 24,461 | 23,354 | 20,985 | 19,476 | 18,998 |
Selling, General & Admin | 7,372 | 7,018 | 7,358 | 7,062 | 7,397 |
Other Operating Expenses | 3,949 | 4,524 | 4,541 | 4,272 | 3,931 |
Operating Expenses | 11,985 | 12,210 | 12,595 | 11,992 | 12,010 |
Operating Income | 12,476 | 11,143 | 8,390 | 7,484 | 6,988 |
Interest Expense | -27.32 | -13.14 | -17.99 | -18.12 | -19.96 |
Interest & Investment Income | 657.3 | 762.8 | 729.28 | 698.55 | 711.53 |
Currency Exchange Gain (Loss) | -47.64 | -22.66 | - | -99.07 | -51.36 |
Other Non Operating Income (Expenses) | - | - | - | - | 37 |
EBT Excluding Unusual Items | 13,058 | 11,870 | 9,101 | 8,066 | 7,666 |
Merger & Restructuring Charges | - | - | -1,633 | -113.7 | -200.84 |
Gain (Loss) on Sale of Investments | 796.3 | 696.5 | 487.76 | 307.79 | 5.92 |
Gain (Loss) on Sale of Assets | -0.46 | -15.13 | 8.89 | 0.28 | 3.24 |
Asset Writedown | - | - | - | - | 2.61 |
Other Unusual Items | 206.25 | 46.92 | 196.87 | 104.02 | 314 |
Pretax Income | 14,060 | 12,599 | 8,162 | 8,364 | 7,790 |
Income Tax Expense | 3,700 | 3,323 | 2,262 | 2,288 | 3,983 |
Earnings From Continuing Operations | 10,360 | 9,276 | 5,900 | 6,076 | 3,808 |
Earnings From Discontinued Operations | - | - | - | 30.45 | 13,140 |
Net Income | 10,360 | 9,276 | 5,900 | 6,107 | 16,947 |
Net Income to Common | 10,360 | 9,276 | 5,900 | 6,107 | 16,947 |
Net Income Growth | 11.69% | 57.23% | -3.39% | -63.97% | 373.19% |
Shares Outstanding (Basic) | 169 | 169 | 169 | 169 | 169 |
Shares Outstanding (Diluted) | 169 | 169 | 169 | 169 | 169 |
EPS (Basic) | 61.15 | 54.76 | 34.83 | 36.05 | 100.04 |
EPS (Diluted) | 61.15 | 54.76 | 34.83 | 36.05 | 100.04 |
EPS Growth | 11.69% | 57.23% | -3.39% | -63.97% | 373.19% |
Free Cash Flow | 8,480 | 12,669 | 5,508 | 4,402 | 7,761 |
Free Cash Flow Per Share | 50.06 | 74.78 | 32.51 | 25.98 | 45.81 |
Dividend Per Share | 57.000 | 42.000 | 32.000 | 32.000 | 30.000 |
Dividend Growth | 35.71% | 31.25% | - | 6.67% | - |
Gross Margin | 64.00% | 62.29% | 60.76% | 59.89% | 57.96% |
Operating Margin | 32.65% | 29.72% | 24.29% | 23.02% | 21.32% |
Profit Margin | 27.11% | 24.74% | 17.08% | 18.78% | 51.70% |
Free Cash Flow Margin | 22.19% | 33.79% | 15.95% | 13.54% | 23.68% |
EBITDA | 12,861 | 11,527 | 8,805 | 7,884 | 7,428 |
EBITDA Margin | 33.65% | 30.75% | 25.50% | 24.25% | 22.66% |
D&A For EBITDA | 384.81 | 383.57 | 415.36 | 399.67 | 439.6 |
EBIT | 12,476 | 11,143 | 8,390 | 7,484 | 6,988 |
EBIT Margin | 32.65% | 29.72% | 24.29% | 23.02% | 21.32% |
Effective Tax Rate | 26.32% | 26.38% | 27.72% | 27.35% | 51.12% |
Revenue as Reported | - | 38,951 | 35,763 | 33,524 | 33,538 |
Advertising Expenses | 1,279 | 1,202 | 1,094 | 1,091 | 1,277 |